9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Estimated reading time: < 1 min

Condition: Cancer

Estimated Enrollment: 34

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs),  Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG),  Part 1: Safety assessment as assessed by vital signs, Part 1: Safety assessment as assessed by change from baseline in laboratory values

Interventions: GSK2256098, Trametinib

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: June 23, 2016

Completion Date: June 23, 2016

Last  Posted Date: July 12, 2019

Location: GSK Investigational Site, Villejuif Cedex, France

Website Link: https://ClinicalTrials.gov/show/NCT01938443

Was this article helpful?
Dislike 0